Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha.

J. C. Morrill, G. B. Jennings, T. M. Cosgriff, P. H. Gibbs, C. J. Peters

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Prophylactic and therapeutic efficacy of recombinant leukocyte A interferon (rIFN-alpha A) and Sendai virus-induced human leukocyte interferon (HuIFN-alpha) administered intramuscularly to Rift Valley fever virus (RVFV)-infected rhesus monkeys was studied. Clinical, virologic, immunologic, and hemostatic parameters were monitored. Five daily inoculations of 5 X 10(5) units of either interferon product per kilogram of body weight, initiated 24 hours before or 6 hours after RVFV infection, prevented or greatly suppressed viremia. No clinical signs of disease or laboratory evidence of impaired hemostasis was observed. Serum neutralizing antibody to RVFV was detected within 6 days of virus inoculation. Prophylactic administration of 5 X 10(4) or 5 X 10(3) units of rIFN-alpha A per kilogram also limited viremia, hepatocellular damage, and hemostatic derangement. Untreated, RVFV-infected, control monkeys developed high-titered viremia, clinical disease, and impaired hemostasis. These data suggest that rIFN-alpha A and HuIFN-alpha are effective in protecting RVFV-infected rhesus monkeys from viremia and hepatocellular damage and may be beneficial in human RVF infection.

Original languageEnglish (US)
JournalReviews of Infectious Diseases
Volume11 Suppl 4
StatePublished - May 1989
Externally publishedYes

Fingerprint

Rift Valley Fever
Rift Valley fever virus
Macaca mulatta
Interferon-alpha
Viremia
Hemostatics
Hemostasis
Alphavirus
Sendai virus
Virus Diseases
Neutralizing Antibodies
Interferons
Haplorhini
Body Weight
Viruses
Infection
Serum

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Morrill, J. C., Jennings, G. B., Cosgriff, T. M., Gibbs, P. H., & Peters, C. J. (1989). Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Reviews of Infectious Diseases, 11 Suppl 4.

Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. / Morrill, J. C.; Jennings, G. B.; Cosgriff, T. M.; Gibbs, P. H.; Peters, C. J.

In: Reviews of Infectious Diseases, Vol. 11 Suppl 4, 05.1989.

Research output: Contribution to journalArticle

Morrill, JC, Jennings, GB, Cosgriff, TM, Gibbs, PH & Peters, CJ 1989, 'Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha.', Reviews of Infectious Diseases, vol. 11 Suppl 4.
Morrill JC, Jennings GB, Cosgriff TM, Gibbs PH, Peters CJ. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Reviews of Infectious Diseases. 1989 May;11 Suppl 4.
Morrill, J. C. ; Jennings, G. B. ; Cosgriff, T. M. ; Gibbs, P. H. ; Peters, C. J. / Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. In: Reviews of Infectious Diseases. 1989 ; Vol. 11 Suppl 4.
@article{24fcea7589014a28975c63785ab68445,
title = "Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha.",
abstract = "Prophylactic and therapeutic efficacy of recombinant leukocyte A interferon (rIFN-alpha A) and Sendai virus-induced human leukocyte interferon (HuIFN-alpha) administered intramuscularly to Rift Valley fever virus (RVFV)-infected rhesus monkeys was studied. Clinical, virologic, immunologic, and hemostatic parameters were monitored. Five daily inoculations of 5 X 10(5) units of either interferon product per kilogram of body weight, initiated 24 hours before or 6 hours after RVFV infection, prevented or greatly suppressed viremia. No clinical signs of disease or laboratory evidence of impaired hemostasis was observed. Serum neutralizing antibody to RVFV was detected within 6 days of virus inoculation. Prophylactic administration of 5 X 10(4) or 5 X 10(3) units of rIFN-alpha A per kilogram also limited viremia, hepatocellular damage, and hemostatic derangement. Untreated, RVFV-infected, control monkeys developed high-titered viremia, clinical disease, and impaired hemostasis. These data suggest that rIFN-alpha A and HuIFN-alpha are effective in protecting RVFV-infected rhesus monkeys from viremia and hepatocellular damage and may be beneficial in human RVF infection.",
author = "Morrill, {J. C.} and Jennings, {G. B.} and Cosgriff, {T. M.} and Gibbs, {P. H.} and Peters, {C. J.}",
year = "1989",
month = "5",
language = "English (US)",
volume = "11 Suppl 4",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha.

AU - Morrill, J. C.

AU - Jennings, G. B.

AU - Cosgriff, T. M.

AU - Gibbs, P. H.

AU - Peters, C. J.

PY - 1989/5

Y1 - 1989/5

N2 - Prophylactic and therapeutic efficacy of recombinant leukocyte A interferon (rIFN-alpha A) and Sendai virus-induced human leukocyte interferon (HuIFN-alpha) administered intramuscularly to Rift Valley fever virus (RVFV)-infected rhesus monkeys was studied. Clinical, virologic, immunologic, and hemostatic parameters were monitored. Five daily inoculations of 5 X 10(5) units of either interferon product per kilogram of body weight, initiated 24 hours before or 6 hours after RVFV infection, prevented or greatly suppressed viremia. No clinical signs of disease or laboratory evidence of impaired hemostasis was observed. Serum neutralizing antibody to RVFV was detected within 6 days of virus inoculation. Prophylactic administration of 5 X 10(4) or 5 X 10(3) units of rIFN-alpha A per kilogram also limited viremia, hepatocellular damage, and hemostatic derangement. Untreated, RVFV-infected, control monkeys developed high-titered viremia, clinical disease, and impaired hemostasis. These data suggest that rIFN-alpha A and HuIFN-alpha are effective in protecting RVFV-infected rhesus monkeys from viremia and hepatocellular damage and may be beneficial in human RVF infection.

AB - Prophylactic and therapeutic efficacy of recombinant leukocyte A interferon (rIFN-alpha A) and Sendai virus-induced human leukocyte interferon (HuIFN-alpha) administered intramuscularly to Rift Valley fever virus (RVFV)-infected rhesus monkeys was studied. Clinical, virologic, immunologic, and hemostatic parameters were monitored. Five daily inoculations of 5 X 10(5) units of either interferon product per kilogram of body weight, initiated 24 hours before or 6 hours after RVFV infection, prevented or greatly suppressed viremia. No clinical signs of disease or laboratory evidence of impaired hemostasis was observed. Serum neutralizing antibody to RVFV was detected within 6 days of virus inoculation. Prophylactic administration of 5 X 10(4) or 5 X 10(3) units of rIFN-alpha A per kilogram also limited viremia, hepatocellular damage, and hemostatic derangement. Untreated, RVFV-infected, control monkeys developed high-titered viremia, clinical disease, and impaired hemostasis. These data suggest that rIFN-alpha A and HuIFN-alpha are effective in protecting RVFV-infected rhesus monkeys from viremia and hepatocellular damage and may be beneficial in human RVF infection.

UR - http://www.scopus.com/inward/record.url?scp=0000652119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000652119&partnerID=8YFLogxK

M3 - Article

VL - 11 Suppl 4

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -